A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis

Clinical Rheumatology

Volumn 30, Issue 11, 2011, Pages 1433-1446

  Schnitzer, Thomas J ^a   Dattani, I Dan ^b   Seriolo, Bruno ^c   Schneider, Hartmut ^d   Moore, Alan ^e   Tseng, Lillian ^e   Sallstig, Peter ^e   Rebuli, Rosemary ^e   Maxwell, Thomas ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF GENOA   (Italy)

^d Facharzt für Orthopädie Sportmedizin   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Little Common and Old Town Surgeries   (United Kingdom)

Author keywords

Anti inflammatory agents; Celecoxib; Cyclooxygenase inhibitors; Hip; Lumiracoxib; nonsteroidal; Osteoarthritis; Randomized controlled trial

Indexed keywords

CELECOXIB; LUMIRACOXIB; PLACEBO;

ADULT; AGED; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HIP OSTEOARTHRITIS; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THORAX PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 80755140179     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1776-4     Document Type: Article

References (20)

1. RC Lawrence CG Helmick FC Arnett RA Deyo DT Felson EH Giannini SP Heyse R Hirsch MC Hochberg GG Hunder MH Liang SR Pillemer VD Steen F Wolfe 1998 Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States Arthritis Rheum 41 778 799 9588729 10.1002/1529- 0131(199805)41:5<778::AID-ART4>3.0.CO;2-V 1:STN:280:DyaK1c3kvVWnsQ%3D%3D (Pubitemid 28225778)
2. Anonymous 2000 Recommendations for the medical management of osteoarthritis of the hip and knee 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Arthritis Rheum 43 1905 1915 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P
3. W Zhang RW Moskowitz G Nuki S Abramson RD Altman N Arden S Bierma-Zeinstra KD Brandt P Croft M Doherty M Dougados M Hochberg DJ Hunter K Kwoh LS Lohmander P Tugwell 2007 OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence Osteoarthritis Cartilage 15 981 1000 17719803 10.1016/j.joca.2007.06.014 1:STN:280: DC%2BD2srktVOmug%3D%3D (Pubitemid 47393443)
4. W Zhang RW Moskowitz G Nuki S Abramson RD Altman N Arden S Bierma-Zeinstra KD Brandt P Croft M Doherty M Dougados M Hochberg DJ Hunter K Kwoh LS Lohmander P Tugwell 2008 OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines Osteoarthritis Cartilage 16 137 162 18279766 10.1016/j.joca.2007.12. 013 1:STN:280:DC%2BD1c7it12itg%3D%3D (Pubitemid 351222155)
5. W Zhang G Nuki RW Moskowitz S Abramson RD Altman NK Arden S Bierma-Zeinstra KD Brandt P Croft M Doherty M Dougados M Hochberg DJ Hunter K Kwoh LS Lohmander P Tugwell 2010 OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009 Osteoarthritis Cartilage 18 476 499 20170770 10.1016/j.joca.2010.01.013 1:CAS:528: DC%2BC3cXhtlajur3N
6. JM Bjordal AE Ljunggren A Klovning L Slordal 2005 NSAIDs, including coxibs, probably do more harm than good, and paracetamol is ineffective for hip OA Ann Rheum Dis 64 655 656 15769931 1:STN:280:DC%2BD2M7jslGgtQ%3D%3D (Pubitemid 40469110)
7. W Makarowski WW Zhao T Bevirt DP Recker 2002 Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen Osteoarthritis Cartilage 10 290 296 11950252 10.1053/joca.2001.0510 1:STN:280:DC%2BD383hsVKmtA%3D%3D (Pubitemid 34467633)
8. AJ Kivitz RW Moskowitz E Woods RC Hubbard KM Verburg JB Lefkowith GS Geis 2001 Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip J Int Med Res 29 467 479 11803730 1:CAS:528:DC%2BD38XmtVahsQ%3D%3D (Pubitemid 34036826)
9. O Svensson M Malmenas L Fajutrao EM Roos LS Lohmander 2006 Greater reduction of knee than hip pain in osteoarthritis treated with naproxen, as evaluated by WOMAC and SF-36 Ann Rheum Dis 65 781 784 16269428 10.1136/ard.2005.040519 1:CAS:528:DC%2BD28XlvVSktLo%3D (Pubitemid 43799178)
10. W Zhang M Doherty N Arden B Bannwarth J Bijlsma KP Gunther HJ Hauselmann G Herrero-Beaumont K Jordan P Kaklamanis B Leeb M Lequesne S Lohmander B Mazieres E Martin-Mola K Pavelka A Pendleton L Punzi B Swoboda R Varatojo G Verbruggen I Zimmermann-Gorska M Dougados EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) 2005 EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 64 669 681 15471891 10.1136/ard.2004.028886 1:STN:280:DC%2BD2M7pvFeqtg%3D%3D (Pubitemid 40559291)
11. R Lehmann M Brzosko P Kopsa R Nischik A Kreiss H Thurston S Litschig VS Sloan 2005 Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib Curr Med Res Opin 21 517 526 15899100 10.1185/030079905X38196 1:CAS:528:DC%2BD2MXltlWms7g%3D (Pubitemid 40676103)
12. E Sheldon A Beaulieu Z Paster D Dutta S Yu VS Sloan 2005 Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo Clin Ther 27 64 77 15763607 10.1016/j.clinthera.2005.01.002 1:CAS:528: DC%2BD2MXis1WltLc%3D (Pubitemid 40342577)
13. F Tubach P Ravaud G Baron B Falissard I Logeart N Bellamy C Bombardier D Felson M Hochberg D van der Heijde M Dougados 2005 Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement Ann Rheum Dis 64 29 33 15208174 10.1136/ard.2004.022905 1:STN:280:DC%2BD2M%2FgslKgtw%3D%3D (Pubitemid 40075270)
14. M Dougados A Moore S Yu X Gitton 2007 Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis Arthritis Res Ther 9 R11 17266764 10.1186/ar2118 (Pubitemid 46336464)
15. K Pavelka O Zamani R Alten S Yu S Litschig VS Sloan 2005 Lumiracoxib is effective and well tolerated in the long-term treatment of knee osteoarthritis [Abstract FRI0319] Ann Rheum Dis 64 Suppl. 3 353
16. TJ Schnitzer GR Burmester E Mysler MC Hochberg M Doherty E Ehrsam X Gitton G Krammer B Mellein P Matchaba A Gimona CJ Hawkey TARGET Study Group 2004 Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial Lancet 364 665 674 15325831 10.1016/S0140-6736(04)16893-1 1:CAS:528:DC%2BD2cXmvFWltrg%3D (Pubitemid 39140622)
17. ME Farkouh H Kirshner RA Harrington S Ruland FW Verheugt TJ Schnitzer GR Burmester E Mysler MC Hochberg M Doherty E Ehrsam X Gitton G Krammer B Mellein A Gimona P Matchaba CJ Hawkey JH Chesebro TARGET Study Group 2004 Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial Lancet 364 675 684 15325832 10.1016/S0140-6736(04)16894-3 1:CAS:528:DC%2BD2cXmvFWltrk%3D (Pubitemid 39140623)
18. R Fleischmann H Tannenbaum NP Patel M Notter P Sallstig J-Y Reginster 2006 Retention on treatment with lumiracoxib in patients with osteoarthritis [Abstract P302] Osteoarthritis Cartilage 14 Suppl. 2 S165 10.1016/S1063-4584(07) 60750-X
19. R Fleischmann E Sheldon J Maldonado-Cocco D Dutta S Yu VS Sloan 2006 Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib Clin Rheumatol 25 42 53 16132165 10.1007/s10067-005-1126-5
20. JB Singer S Lewitzky E Leroy F Yang X Zhao L Klickstein TM Wright J Meyer CA Paulding 2010 A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury Nat Genet 42 711 714 20639878 10.1038/ng.632 1:CAS:528:DC%2BC3cXovFCgur4%3D